Neurodegeneration Therapeutic Target Comparison Matrix

📖 Wiki Page

therapeutic1497 wordssynced 2026-04-02

Neurodegeneration Therapeutic Target Comparison Matrix

Overview

...

Neurodegeneration Therapeutic Target Comparison Matrix

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neurodegeneration Therapeutic Target Comparison Matrix</th>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">Amyloid-beta</td>
<td>[APP](/genes/app)</td>
</tr>
<tr>
<td class="label">Tau protein</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">TDP-43</td>
<td>TARDBP</td>
</tr>
<tr>
<td class="label">FUS protein</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">BACE1</td>
<td>[BACE1](/genes/bace1)</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>[TREM2](/genes/trem2)</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>[APOE](/genes/apoe)</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>[LRRK2](/genes/lrrk2)</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>GBA</td>
</tr>
<tr>
<td class="label">SNCA</td>
<td>[SNCA](/genes/snca)</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>[C9orf72](/genes/c9orf72)</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Lecanemab</td>
<td>Aβ (protofibrils)</td>
</tr>
<tr>
<td class="label">Donanemab</td>
<td>Aβ (plaques)</td>
</tr>
<tr>
<td class="label">Cinpanemab</td>
<td>α-Syn</td>
</tr>
<tr>
<td class="label">Prasinezumab</td>
<td>α-Syn</td>
</tr>
<tr>
<td class="label">Semorinemab</td>
<td>Tau</td>
</tr>
<tr>
<td class="label">AL002</td>
<td>TREM2</td>
</tr>
<tr>
<td class="label">ASO</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Tofersen</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>[SOD1](/genes/sod1)</td>
</tr>
<tr>
<td class="label">BIIB080</td>
<td>[MAPT](/genes/mapt)</td>
</tr>
<tr>
<td class="label">ION363</td>
<td>[FUS](/genes/fus)</td>
</tr>
<tr>
<td class="label">ASO-C9orf72</td>
<td>[C9orf72](/genes/c9orf72)</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Target</td>
</tr>
<tr>
<td class="label">AAV-GDNF</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">AAV-BDNF</td>
<td>BDNF</td>
</tr>
<tr>
<td class="label">PBFT02</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">AVB-101</td>
<td>[GRN](/genes/grn)</td>
</tr>
<tr>
<td class="label">Zolgensma</td>
<td>SMN1</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">GLP-1 agonists</td>
<td>GLP-1R</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>mTOR</td>
</tr>
<tr>
<td class="label">Nilotinib</td>
<td>BCR-ABL/c-Abl</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90</td>
</tr>
<tr>
<td class="label">Target</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Aβ (APP/BACE1)</td>
<td>●●●</td>
</tr>
<tr>
<td class="label">Tau (MAPT/GSK3B)</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">α-Syn (SNCA/LRRK2)</td>
<td>○</td>
</tr>
<tr>
<td class="label">TREM2</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">APOE</td>
<td>●●○</td>
</tr>
<tr>
<td class="label">SOD1</td>
<td>—</td>
</tr>
<tr>
<td class="label">C9orf72</td>
<td>—</td>
</tr>
<tr>
<td class="label">FUS</td>
<td>—</td>
</tr>
<tr>
<td class="label">GRN</td>
<td>○</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Anti-amyloid</td>
<td>3</td>
</tr>
<tr>
<td class="label">Anti-tau</td>
<td>2</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>4</td>
</tr>
<tr>
<td class="label">Metabolic</td>
<td>2</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">Disease modification</td>
<td>2</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>1</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>—</td>
</tr>
<tr>
<td class="label">α-Syn targeting</td>
<td>2</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">SOD1 targeting</td>
<td>1</td>
</tr>
<tr>
<td class="label">C9orf72 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Neuroprotection</td>
<td>3</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>—</td>
</tr>
<tr>
<td class="label">Category</td>
<td>Phase 3</td>
</tr>
<tr>
<td class="label">GRN targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">C9orf72 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Tau targeting</td>
<td>1</td>
</tr>
<tr>
<td class="label">TDP-43 targeting</td>
<td>—</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>AD</td>
</tr>
<tr>
<td class="label">Neuroinflammation</td>
<td>●</td>
</tr>
<tr>
<td class="label">Protein aggregation</td>
<td>●</td>
</tr>
<tr>
<td class="label">Mitochondrial dysfunction</td>
<td>●</td>
</tr>
<tr>
<td class="label">Autophagy impairment</td>
<td>●</td>
</tr>
<tr>
<td class="label">Oxidative stress</td>
<td>●</td>
</tr>
</table>

This page provides a comprehensive comparison of therapeutic targets across major neurodegenerative diseases: Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Frontotemporal Dementia (FTD). The matrix covers protein aggregation targets, genetic risk factors, and disease-modifying approaches with their clinical development status.

Therapeutic Target Comparison Matrix

Protein Aggregation Targets

Genetic Risk Factor Targets

Disease-Modifying Therapeutic Modalities

Immunotherapies

Antisense Oligonucleotides (ASOs)

Gene Therapy Approaches

Small Molecule Modulators

Target-Disease Coverage Matrix

Legend: ●●● = Primary disease target, ●●○ = Active development, ○ = Research/preclinical

Clinical Development Status Summary

Alzheimer's Disease (2026)

Parkinson's Disease (2026)

ALS (2026)

FTD (2026)

Cross-Disease Therapeutic Opportunities

Shared Mechanisms

Multi-Disease Targets in Development

GLP-1 Receptor Agonists: Active in AD and PD trials (semaglutide, liraglutide)

TREM2 Modulators: Microglial targeting in AD, potential for FTD

NLRP3 Inhibitors: Neuroinflammation across diseases

Autophagy Enhancers: Protein clearance (rapamycin, urolithin A)

mTOR Modulators: Shared pathway in AD, PD, ALS

Challenges and Considerations

Common Challenges

Biomarker validation: Correlating biomarker changes with clinical outcomes

Patient stratification: Genetic and biomarker-based selection

Delivery to CNS: BBB penetration remains a key hurdle

Timing of intervention: Early intervention likely more effective

Combination approaches: Synergistic targeting of multiple pathways

Disease-Specific Challenges

AD: Heterogeneous pathology (Aβ, tau, inflammation)
PD: Alpha-synuclein spread and alpha-synucleinopathy subtypes
ALS: Rapid progression, multiple genetic causes
FTD: Phenotypic heterogeneity, overlapping pathology

Therapeutic Pages

[AD/PD Target Comparison Matrix](/therapeutics/ad-pd-target-comparison-matrix)
[Immunotherapy Comparison](/therapeutics/immunotherapy-comparison)
[SOD1-Targeting Therapies](/therapeutics/sod1-targeting-therapies)
[Progranulin Therapy](/therapeutics/progranulin-therapy)
[TREM2-Targeting Therapeutics](/therapeutics/trem2-therapeutics)
[LRRK2 Inhibitors](/therapeutics/lrrk2-inhibitors)
[ASO C9orf72 ALS](/therapeutics/aso-c9orf72-als)
[FUS-ALS Treatment](/therapeutics/fus-als-treatment)

Gene/Protein Pages

[APP Gene](/genes/app) | [APP Protein](/proteins/app)
[BACE1 Gene](/genes/bace1) | [BACE1 Protein](/proteins/bace1)
[MAPT Gene](/genes/mapt) | [Tau Protein](/proteins/tau)
[GSK3B Gene](/genes/gsk3b) | [GSK3β Protein](/proteins/gsk3b)
[SNCA Gene](/genes/snca) | [α-Synuclein](/proteins/alpha-synuclein)
[LRRK2 Gene](/genes/lrrk2) | [LRRK2 Protein](/proteins/lrrk2)
[TREM2 Gene](/genes/trem2) | [TREM2 Protein](/proteins/trem2)
[APOE Gene](/genes/apoe) | [APOE Protein](/proteins/apoe)
[SOD1 Gene](/genes/sod1) | [SOD1 Protein](/proteins/sod1)
[C9orf72 Gene](/genes/c9orf72) | [C9orf72 Protein](/proteins/c9orf72)
[FUS Gene](/genes/fus) | [FUS Protein](/proteins/fus)
[GRN Gene](/genes/grn) | [Progranulin](/proteins/progranulin)

Disease Pages

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
[Frontotemporal Dementia](/diseases/frontotemporal-dementia)
[Corticobasal Syndrome](/diseases/corticobasal-syndrome)
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-psp)

References

[Cummings et al., Alzheimer's disease drug development pipeline (2024)](https://doi.org/10.1002/alz.13858)

[Pagano et al., Parkinson's disease drug pipeline (2024)](https://doi.org/10.1038/s41573-024-00936-1)

[Miller et al., Tofersen in SOD1-ALS (2022)](https://doi.org/10.1056/NEJMoa2204707)

[Mummery et al., AL002 in early AD Phase 2 (2026)](https://pubmed.ncbi.nlm.nih.gov/41787076)

[Baker et al., Mutations in progranulin cause FTD (2006)](https://doi.org/10.1038/nature05017)

[Guerreiro et al., TREM2 variants in AD (2013)](https://doi.org/10.1056/NEJMoa1208120)

[Rosen et al., SOD1 mutations in familial ALS (1993)](https://doi.org/10.1038/364362c0)

Pathway Diagram

The following diagram shows the key molecular relationships involving Neurodegeneration Therapeutic Target Comparison Matrix discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC
[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
[Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) 🔄

📖 View canonical wiki page →

Neurodegeneration Therapeutic Target Comparison Matrix

Neurodegeneration Therapeutic Target Comparison Matrix

Overview

Neurodegeneration Therapeutic Target Comparison Matrix

Overview

Therapeutic Target Comparison Matrix

Protein Aggregation Targets

Genetic Risk Factor Targets

Disease-Modifying Therapeutic Modalities

Immunotherapies

Antisense Oligonucleotides (ASOs)

Gene Therapy Approaches

Small Molecule Modulators

Target-Disease Coverage Matrix

Clinical Development Status Summary

Alzheimer's Disease (2026)

Parkinson's Disease (2026)

ALS (2026)

FTD (2026)

Cross-Disease Therapeutic Opportunities

Shared Mechanisms

Multi-Disease Targets in Development

Challenges and Considerations

Common Challenges

Disease-Specific Challenges

Related Pages

Therapeutic Pages

Gene/Protein Pages

Disease Pages

References

Pathway Diagram

Related Hypotheses